KR101417201B1 - 신경변성 질환을 치료하기 위한 조성물 및 방법 - Google Patents

신경변성 질환을 치료하기 위한 조성물 및 방법 Download PDF

Info

Publication number
KR101417201B1
KR101417201B1 KR1020107015422A KR20107015422A KR101417201B1 KR 101417201 B1 KR101417201 B1 KR 101417201B1 KR 1020107015422 A KR1020107015422 A KR 1020107015422A KR 20107015422 A KR20107015422 A KR 20107015422A KR 101417201 B1 KR101417201 B1 KR 101417201B1
Authority
KR
South Korea
Prior art keywords
cla
ala
phenylalanine
coenzyme
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020107015422A
Other languages
English (en)
Korean (ko)
Other versions
KR20100098553A (ko
Inventor
시니치 소메야
Original Assignee
마린 바이오 씨오., 엘티디.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 마린 바이오 씨오., 엘티디. filed Critical 마린 바이오 씨오., 엘티디.
Publication of KR20100098553A publication Critical patent/KR20100098553A/ko
Application granted granted Critical
Publication of KR101417201B1 publication Critical patent/KR101417201B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020107015422A 2008-01-02 2008-12-31 신경변성 질환을 치료하기 위한 조성물 및 방법 Expired - Fee Related KR101417201B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1859408P 2008-01-02 2008-01-02
US61/018,594 2008-01-02
PCT/US2008/088660 WO2009088939A2 (en) 2008-01-02 2008-12-31 Compositions and methods for treating neurodegenerative diseases

Publications (2)

Publication Number Publication Date
KR20100098553A KR20100098553A (ko) 2010-09-07
KR101417201B1 true KR101417201B1 (ko) 2014-07-08

Family

ID=40798719

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107015422A Expired - Fee Related KR101417201B1 (ko) 2008-01-02 2008-12-31 신경변성 질환을 치료하기 위한 조성물 및 방법

Country Status (6)

Country Link
US (2) US8168675B2 (enExample)
EP (1) EP2237777A4 (enExample)
JP (1) JP5575662B2 (enExample)
KR (1) KR101417201B1 (enExample)
CN (1) CN101945653B (enExample)
WO (1) WO2009088939A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3174544B1 (en) 2014-07-31 2020-12-09 Universita' Degli Studi Di Cagliari Ester of a phospholipid with conjugated linoleic acid for the treatment of psychiatric disorders with neuroinflammatory and neurodegenerative basis
EP3903776A4 (en) * 2018-12-25 2022-10-05 Demencare Laboratory Inc. COMPOSITION FOR IMPROVING COGNITIVE FUNCTIONS
KR102557719B1 (ko) * 2019-04-26 2023-07-20 가톨릭대학교 산학협력단 항산화제가 담지된 나노입자를 유효성분으로 포함하는 귀 질환 치료용 약학 조성물
CN113892460A (zh) * 2021-09-29 2022-01-07 滨州医学院 Nod-b6重组近交系小鼠模型的构建方法及应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020177558A1 (en) * 2000-04-21 2002-11-28 Meyerhoff James L. Method of treating, preventing or inhibiting central nervous system injuries and diseases
US20030055099A1 (en) * 2001-09-19 2003-03-20 Martynyuk Anatoly E. Materials and methods for treatment of neurological disorders involving overactivation of glutamatergic ionotropic receptors
US20060078549A1 (en) * 2004-10-13 2006-04-13 U.S. Department Of Veterans Affairs Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as huntington's disease, by using coenzyme Q10

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2543587B2 (ja) * 1989-01-05 1996-10-16 帝人株式会社 語音聴力改善剤
US5670539A (en) * 1993-07-21 1997-09-23 New York State Office Of Mental Health Treatment of movement disorders using large neutral amino acids
US5977162A (en) * 1996-09-16 1999-11-02 Seidman; Michael D. Therapeutic treatment for auditory function
IT1290907B1 (it) * 1997-01-31 1998-12-14 Idi Farmaceutici Spa Composizione per prodotto dietetico efficace nel combattere lo stress ossidativo e il decadimento cellulare.
US6080788A (en) * 1997-03-27 2000-06-27 Sole; Michael J. Composition for improvement of cellular nutrition and mitochondrial energetics
GB0003310D0 (en) * 2000-02-15 2000-04-05 Univ Sheffield Bone formation
DE10027968A1 (de) * 2000-06-08 2001-12-13 Asta Medica Ag Mittel zur Therapie von Demenzen
CN1105097C (zh) * 2000-09-14 2003-04-09 国家海洋局第一海洋研究所 微囊化共轭亚油酸
US20030045541A1 (en) * 2001-07-23 2003-03-06 Christopher Bruckner GABA-Receptor modulators with NMDA-Antagonistic activity
US7438903B2 (en) * 2003-06-06 2008-10-21 Nbty, Inc. Methods and compositions that enhance bioavailability of coenzyme-Q10
US20050107338A1 (en) * 2003-11-17 2005-05-19 Seidman Michael D. Nutritional supplement enhancing mitochondrial function
AR048335A1 (es) * 2004-03-24 2006-04-19 Chugai Pharmaceutical Co Ltd Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo
JP2006151909A (ja) * 2004-11-30 2006-06-15 Rohto Pharmaceut Co Ltd 内服用組成物
CN1850065A (zh) * 2005-04-23 2006-10-25 中山市尤利卡天然药物有限公司 口服共轭亚油酸及其衍生物用于增肌健体与皮肤美容的用途
JP2007023028A (ja) * 2005-06-16 2007-02-01 Ono Pharmaceut Co Ltd 内耳疾患治療剤
JP2006212021A (ja) * 2005-08-05 2006-08-17 Ajinomoto Co Inc 食品組成物
US20080234197A1 (en) * 2007-03-19 2008-09-25 Undurti N Das Method(s) of stabilizing and potentiating the actions and administration of brain-derived neurotrophic factor (BDNF)

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020177558A1 (en) * 2000-04-21 2002-11-28 Meyerhoff James L. Method of treating, preventing or inhibiting central nervous system injuries and diseases
US20030055099A1 (en) * 2001-09-19 2003-03-20 Martynyuk Anatoly E. Materials and methods for treatment of neurological disorders involving overactivation of glutamatergic ionotropic receptors
US20060078549A1 (en) * 2004-10-13 2006-04-13 U.S. Department Of Veterans Affairs Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as huntington's disease, by using coenzyme Q10

Also Published As

Publication number Publication date
WO2009088939A3 (en) 2009-09-11
WO2009088939A2 (en) 2009-07-16
US20090169533A1 (en) 2009-07-02
US20120189600A1 (en) 2012-07-26
CN101945653A (zh) 2011-01-12
EP2237777A2 (en) 2010-10-13
EP2237777A4 (en) 2011-03-30
US8168675B2 (en) 2012-05-01
KR20100098553A (ko) 2010-09-07
CN101945653B (zh) 2013-01-16
JP2011509257A (ja) 2011-03-24
JP5575662B2 (ja) 2014-08-20

Similar Documents

Publication Publication Date Title
US6335361B1 (en) Method of treating benign forgetfulness
US20070179197A1 (en) Compositions and methods for improving or preserving brain function
WO2011082111A1 (en) Anaplerotic therapy for alzheimer's disease and the aging brain
US20240024340A1 (en) Compositions and Methods For Treating Migraine
Balietti et al. Ketogenic diets: an historical antiepileptic therapy with promising potentialities for the aging brain
JP2014512351A (ja) 神経障害の治療用組成物
CA2837926A1 (en) Scyllo - inositol for the treatment of behavioral and psychiatric disorders
US20120263698A1 (en) Treatment of Neurodegenerative Disease
CA2677892A1 (en) Neurogenic compounds
KR101417201B1 (ko) 신경변성 질환을 치료하기 위한 조성물 및 방법
Wu et al. Up-regulation of neprilysin mediates the protection of fructo-oligosaccharides against Alzheimer's disease
Ntsapi et al. Dietary Impact on Neuronal Autophagy Control and Brain
JP2021519330A (ja) ムメフラールを含む認知障害関連疾患の予防又は治療用組成物
WO2018002937A1 (en) Combinations of beta-glycolipides and 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol, compositions and uses thereof in the treatment of disorders associated with protein misfolding and protein aggregations
Masuoka et al. Influence of Imidazole-Dipeptides on Cognitive Status and Preservation in Elders: A Narrative Review. Nutrients 2021, 13, 397
RU2654713C1 (ru) Фармацевтическая композиция, содержащая комбинацию мемантина и мелатонина
CA2908378A1 (en) Treatment or prevention of depression using menthol and/or icilin
EP2278982B1 (en) Compositions and methods for treating neurodegenerative diseases
Cardinali et al. Therapeutical implications of melatonin in Alzheimer’s and Parkinson’s diseases
MCLEAN Gabapentin and pregabalin
Casadesus ANTIOXIDANTS: ARE THEY EQUIPOTENT IN ALTERING
Green Environmental tauopathies
Casadesus Stellwagen", & James A. Joseph

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
J201 Request for trial against refusal decision
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20170627

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20180626

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20190625

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20230702

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20230702